Discover March 2025’s top biotech deals, featuring major collaborations in small molecules, bispecific antibodies and protein ...

AstraZeneca has vowed to spend over $10 billion on R&D deals in Asia, focusing on China, amid ongoing fraud scandal ...

Cambridge-headquartered AstraZeneca is investing $2.5 billion in Beijing to establish its sixth global strategic R & D centre ...

AstraZeneca's booth is seen during an expo in Beijing in November. The pharma company announced an investment of $2.5 billion to establish a global R&D center in Beijing. CHINA DAILY Multinational ...

AstraZeneca signed a deal with Alteogen worth up to $1.35 billion for subcutaneous cancer drugs. Taiho Pharmacetical bought ...

Pfizer divested 7.3% remaining stake in Haleon, or approximately 662 million shares, to institutional investors and Haleon itself for £3.85 per ordinary share (around £2.5 billion). Pfizer sold ...

This week, the FDA approved J&J’s JNJ Tremfya for its second inflammatory bowel disease (“IBD”) condition, Crohn’s disease (“CD”), and Novartis’ NVS Fabhalta for its third indication, C3 ...

AstraZeneca has tapped Korea's Alteogen to develop subcutaneous cancer drugs. Taiho Pharmaceutical is paying $400 million to acquire antibody-drug conjugate expert Araris Biotech. WuXi AppTec ...

Illustrated by Kim Hyun-kook On March 17, Alteogen, the largest company by market capitalization on the Kosdaq, announced a $1.35 billion licensing agreement with MedImmune, the R&D subsidiary of ...

Speaking to the Commons business and trade select committee on Tuesday, AstraZeneca’s chairman Shaun Grady confirmed that delays in securing a £90 million government contribution led to the collapse ...

AstraZeneca, a global, science-led biopharmaceutical company, and Alteogen Inc., a South Korea-based biopharmaceutical company that focuses on the development and commercialization of novel biologics ...

Alteogen's landscape ... a U.S. subsidiary of AstraZeneca. The total contract value is $1.35 billion (about 1.964 trillion won), and the contract fee is $45 million (about 65.2 billion won).